Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H James Wallace

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Health Communication|October 10, 2022
Exploring Patients' Trust from a New Perspective. A Text-Analysis StudyBarbara Colombo, Benjamin Aurelio, H James Wallace, et al.
Human Cell|March 1, 2013
Gene expression as a biomarker for human radiation exposureRomaica A Omaruddin, Thomas A Roland, H James Wallace, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 28, 2014
Prognosis of hepatoid yolk sac tumor in women: what's up, Doc?Kristsanamon Rittiluechai, Rebecca Wilcox, Jennifer Lisle, et al.
Case Reports in Oncological Medicine|December 4, 2015
Urothelial Superior Vena Cava Syndrome with Limited Response to Radiation TherapyNishan Bingham, H James Wallace Iii, Joanne Monterroso, et al.
JAMA Network Open|January 13, 2021
Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate CancerNataniel H Lester-Coll, Steven Ades, James B Yu, et al.
Advances in Radiation Oncology|January 25, 2021
Development of Rapid Response Plan for Radiation Oncology in Response to CyberattackCarl J Nelson, Nataniel H Lester-Coll, Puyao C Li, et al.
Urology|December 23, 2008
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapyDonald S Kaufman, Kathryn A Winter, William U Shipley, et al.
Critical Reviews in Eukaryotic Gene Expression|June 24, 2024
A MicroRNA Approach to Evaluating Elevated Prostate Cancer Risk in Cancer-Free MenScott D Perrapato, Nicholas H Farina, Adrian N Berg, et al.
Advances in Radiation Oncology|September 23, 2022
Impact of and Response to Cyberattacks in Radiation OncologyCarl J Nelson, Emilie T Soisson, Puyao C Li, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2015
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233Timur Mitin, Asha George, Anthony L Zietman, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Health Communication|October 10, 2022
Exploring Patients' Trust from a New Perspective. A Text-Analysis StudyBarbara Colombo, Benjamin Aurelio, H James Wallace, et al.
Human Cell|March 1, 2013
Gene expression as a biomarker for human radiation exposureRomaica A Omaruddin, Thomas A Roland, H James Wallace, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 28, 2014
Prognosis of hepatoid yolk sac tumor in women: what's up, Doc?Kristsanamon Rittiluechai, Rebecca Wilcox, Jennifer Lisle, et al.
Case Reports in Oncological Medicine|December 4, 2015
Urothelial Superior Vena Cava Syndrome with Limited Response to Radiation TherapyNishan Bingham, H James Wallace Iii, Joanne Monterroso, et al.
JAMA Network Open|January 13, 2021
Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate CancerNataniel H Lester-Coll, Steven Ades, James B Yu, et al.
Advances in Radiation Oncology|January 25, 2021
Development of Rapid Response Plan for Radiation Oncology in Response to CyberattackCarl J Nelson, Nataniel H Lester-Coll, Puyao C Li, et al.
Urology|December 23, 2008
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapyDonald S Kaufman, Kathryn A Winter, William U Shipley, et al.
Critical Reviews in Eukaryotic Gene Expression|June 24, 2024
A MicroRNA Approach to Evaluating Elevated Prostate Cancer Risk in Cancer-Free MenScott D Perrapato, Nicholas H Farina, Adrian N Berg, et al.
Advances in Radiation Oncology|September 23, 2022
Impact of and Response to Cyberattacks in Radiation OncologyCarl J Nelson, Emilie T Soisson, Puyao C Li, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2015
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233Timur Mitin, Asha George, Anthony L Zietman, et al.
Pageof 2